BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CNS Disease Analysis: Epilepsy

May 06, 2022

The traditional antiepileptic drug (AED) market is highly genericized and there are limited branded AEDs left without generic equivalents. Additionally, though these newer branded AEDs differentiate themselves from older ones, there are still unmet needs in this market to be addressed, including refractory epilepsy and rare specific epilepsies. 

The partial-onset seizure (POS) market represents the largest market in the epilepsy disease space; however, it is highly saturated with an extensive repertoire of anticonvulsants available for prescription. Primary drugs in this patient segment are the broad-label leaders Keppra/Keppra XR, Lamictal/Lamictal XR, and Vimpat. GlaxoSmithKline has managed to slow the ensuing generic erosion of Lamictal/Lamictal XR, but UCB has not been so successful with Keppra/Keppra XR, and sees significant sales only remaining in Japan. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Dravet Syndrome (Epilepsy)
Infantile Spasms (West Syndrome; Epilepsy)
Lennox-Gastaut Syndrome (LGS; Epilepsy)
Partial Seizures (Epilepsy)
Seizure Disorders (Epilepsy)
Back to the top Back to the top